La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Tianda Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Tianda Pharmaceuticals' Il CEO è Alan Fang, nominato in Feb2017, ha un mandato di 7.5 anni. possiede direttamente 56.72% delle azioni della società, per un valore di HK$ 259.77M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.5 anni e 10.9 anni.

Informazioni chiave

Alan Fang

Amministratore delegato

HK$60.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.5yrs
Proprietà del CEO	56.7%
Durata media del management	7.5yrs
Durata media del Consiglio di amministrazione	10.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

AMMINISTRATORE DELEGATO

Alan Fang (55 yo)

7.5yrs

Mandato

HK$60,000

Compensazione

Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Wen Quan Fang	Executive Chairman & MD	7.5yrs	HK$60.00k	56.72% HK$ 292.7m
Man Sang Lui	Executive Director	10.9yrs	HK$72.00k	Nessun dato
Man Yuk Wong	Financial Controller	4.6yrs	Nessun dato	Nessun dato
Tai On Lo	Company Secretary	no data	Nessun dato	Nessun dato

7.5yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di 455 è esperto e expertise (durata media dell'incarico 7.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Wen Quan Fang	Executive Chairman & MD	20.8yrs	HK$60.00k	56.72% HK$ 292.7m
Man Sang Lui	Executive Director	10.9yrs	HK$72.00k	Nessun dato
Sung Hong Chiu	Independent Non-Executive Director	16.3yrs	HK$72.00k	Nessun dato
Yat-Fai Lam	Independent Non-Executive Director	19.9yrs	HK$72.00k	Nessun dato
Tao Zhong	Non-Executive Director	less than a year	HK$25.00k	Nessun dato
Quanming Feng	Non-Executive Director	8.4yrs	Nessun dato	Nessun dato
Yanfang Xian	Independent Non-executive Director	1.2yrs	HK$37.00k	Nessun dato

10.9yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 455 è composto da personale esperto e esperto (durata media dell'incarico 10.9 anni).

Tianda Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Announces Board Changes

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Recent updates

New minor risk - Share price stability

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Tianda Pharmaceuticals Limited to Report First Half, 2024 Results on Aug 28, 2024

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media